drugset / Trial / NCT01320345
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
Phase 3
Active not recruiting
412 enrolled
University of Sydney
Juvenile Diabetes Research Foundation Australia · collabMylan Pharmaceuticals Inc · collabNational Health and Medical Research Council, Australia · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.
Timeline
- Start
- 2016-11-03
- Primary completion
- 2026-08-28
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fenofibrate | Small molecule | 145 mg | Oral |